Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) has announced a strategic collaboration with Ascension, enhancing access to lab services across 10 states in the U.S. Labcorp will manage Ascension’s hospital labs and acquire select outreach lab assets. This partnership aims to improve patient care by leveraging Labcorp's expertise in areas like oncology and neurology. The transactions, pending regulatory approval, are expected to close in the first half of 2022, marking a significant step in Labcorp's mission to innovate healthcare.
Labcorp (NYSE: LH) has announced the opening of a new diagnostics laboratory in South Bend, Indiana, aimed at enhancing service levels for patients and physicians in the region. This 25,000-square-foot facility includes advanced capabilities for microbiology testing and STAT testing, expediting results for urgent tests. Currently employing 100 individuals, the lab aims to improve patient diagnoses and outcomes. The opening builds on Labcorp's prior acquisition of South Bend Medical Foundation’s diagnostic business in October 2019, further expanding service access in Indiana and surrounding states.
Labcorp (NYSE: LH) has launched Labcorp OnDemand, a digital platform allowing consumers to purchase popular tests online and choose to collect samples from home or visit one of 2,000 Labcorp Patient Service Centers. The platform includes tests for wellness, allergies, COVID-19, women's health, and fertility, facilitating better health management. Tests are available with zero upfront costs for eligible individuals. The company plans to expand its offerings through healthcare providers and employers later this year.
Big Health announces Gabriela Perez as its new Chief Commercial Officer to lead global commercial growth and strategy. With over 20 years of experience in healthcare technology, Perez previously managed significant growth at Ovia Health, which was acquired by Labcorp (NYSE: LH) in August 2021. She also contributed to Best Doctors, acquired by Teladoc Health (NYSE: TDOC) in June 2017. Under her leadership, Big Health aims to enhance coverage and reimbursement for digital therapeutics, leveraging its innovative products proven effective in mental health treatment.
Labcorp has launched the Enhanced Liver Fibrosis (ELF™) test, aiming to assess the risk of disease progression in patients with advanced chronic liver disease. This blood test, developed by Siemens Healthineers, has received De Novo marketing authorization from the FDA. It provides a numeric score for patients suffering from nonalcoholic steatohepatitis (NASH), enabling better treatment decisions. Approximately 20 million Americans are affected by NASH, highlighting an urgent need for improved diagnostics in this silent epidemic.
Labcorp's OmniSeq has integrated GenomOncology's Pathology Workbench to enhance its OmniSeq INSIGHT test, a genomic and immune profiling tool for solid tumors. This system analyzes 523 genes, providing insights into mutations, copy number alterations, and immune gene expression. The partnership aims to streamline variant interpretation and improve turnaround times for precision medicine. After Labcorp's acquisition of OmniSeq in June 2021, the INSIGHT test is available to U.S. clinicians and global biopharmaceuticals through Labcorp Drug Development.
Labcorp (NYSE: LH) will announce its Q4 2021 and full-year results on February 10, 2022, before the market opens. A conference call is scheduled for 9 a.m. ET on the same day, allowing stakeholders to discuss the financial outcomes. The earnings report and detailed information will be available on the Labcorp Investor Relations website. Additionally, an audio replay of the call will be accessible until February 24, 2022. Labcorp reported $14 billion in revenue for FY2020, with over 70,000 employees serving clients globally.
Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, at 4:30 p.m. ET. A live webcast will be available on the company's website, providing insights into its operations and strategies. Labcorp is a global life sciences leader, generating $14 billion in revenue in FY2020 and employing over 70,000 staff across more than 100 countries, focusing on diagnostics and drug development.
Labcorp (NYSE: LH) announced a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, for $450 million in cash and up to $125 million based on future performance milestones. This acquisition will enhance Labcorp's oncology portfolio and improve access to precision diagnostics globally, supporting better patient outcomes in cancer care. PGDx's innovative liquid biopsy capabilities align with Labcorp's strategic priorities, with projected revenues from PGDx expected to almost double from $22 million in 2021 to $40 million in 2022.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
